Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies
Multiple Myeloma
Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies
State of the Art in the Management of Relapsed/Refractory Multiple Myeloma: Venetoclax Provides the First Personalized Targeted Therapy for t(11;14) MM
FEATURING
Kenneth Shain
- 78 views
- January 27, 2020